Recommended monitoring during and after treatment of CanL
|Sick treated dogs||Clinically healthy infected dogs|
| Clinical history and physical examination
CBC, biochemical profile ± serum electrophoresis
Complete urinalysis ±UPC
|After the first month of treatment and then every 3-4 months during the first year.
Later on, every 6-12 months in dogs fully recovered clinically with treatment.
|Every 3-6 months|
|Quantitative serology*||Not before 6 months after initial treatment and every 6-12 months.||Every 3-6 months|
|Real-time PCR (optional)||At the same time as serology.||Every 3-6 months|
CBC: complete blood count; UPC: urinary protein:creatinine ratio.
* Some dogs have a significant decrease in antibody levels (i.e. more than three two-fold dilutions difference between monitoring samples) associated with clinical improvement within 6-12 months of therapy. A marked increase in antibody levels (i.e. more than three two-fold dilutions difference between monitoring samples) should be interpreted as a marker of disease relapse, especially in dogs following the discontinuation of treatment.
Management of Leishmania-seropositive but clinically healthy dogs (not vaccinated) and of PCR-positive but seronegative dogs
It is recommended to use serology alone or the combination of serology with PCR for screening healthy dogs and to avoid screening clinically healthy dogs (not vaccinated) only by PCR.
Confirmed low seropositive dogs should be monitored with physical examinations, routine laboratory and serological tests on a regular basis every 3-6 months to assess the possible progression of infection towards disease.